Journals / MN Oftalmoloji / 2012 / Cilt: 19 - Sayı: 4

Which method should be used for evaluating the activity of thyroid orbitopathy: Clinical activity score or urinary glycosaminoglycan level?

Tiroid orbitopati aktivitesinin değerlendirilmesinde hangi yöntemi kullanalım: Klinik aktivite skoru?

Pages
232–236
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: As CAS includes subjective criteria, it is not sufficient when used alone for evaluating the activity of orbitopathy, however, urinary GAG levels, rather than being an effective parameter by itself, should be considered as an adjunctive parameter

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The present study aimed to evaluate the relation between clinical activity score (CAS) and urinary glycosaminoglycan (GAG) level, both of which are frequently used in determining the activation of orbitopathy.
📊
Key Findings & Data:Material and Method: A total of 191 thyroid orbitopathy (TO) patients were evaluated.
💡
Conclusion & Impact:Conclusion: As CAS includes subjective criteria, it is not sufficient when used alone for evaluating the activity of orbitopathy, however, urinary GAG levels, rather than being an effective parameter by itself, should be considered as an adjunctive parameter
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: The present study aimed to evaluate the relation between clinical activity score (CAS) and urinary glycosaminoglycan (GAG) level, both of which are frequently used in determining the activation of orbitopathy. Material and Method: A total of 191 thyroid orbitopathy (TO) patients were evaluated. In order to assess the activity of TO, CAS classification system was used; orbitopathy was considered inactive when CAS <4 and active when CAS &#8805; 4. For urinary GAG measurements, 24 hours&#8217; urine was collected. Urinary GAG analysis was performed according to the dimethylmethylene blue method. Results: A total of 191 cases with TO were grouped according to the clinical activity of eye findings (43 active, 148 inactive). When the relation between the activity of TO and urinary GAG measurements was evaluated, it was demonstrated that mean urinary GAG levels were high in cases with active orbitopathy but the difference was not statistically significant (p=0.538, Mann-Whitney U test). Conclusion: As CAS includes subjective criteria, it is not sufficient when used alone for evaluating the activity of orbitopathy, however, urinary GAG levels, rather than being an effective parameter by itself, should be considered as an adjunctive parameter

Özet

Amaç: Çalışmamızda; tiroid orbitopati (TO) tedavi kararı ve etkinliğini belirlemede önemli kriterlerlerin başında gelen orbitopati aktivitesinin belirlenmesinde sıklıkla kullanılan klinik aktivite skoru (KAS) ile idrar glikozaminoglikan (GAG) ilişkisinin değerlendirilmesi amaçlanmıştır. Gereç ve Yöntem: Bu çalışma kapsamında, TO tanısı ile takip edilmekte olan 191 olgu değerlendirildi. TO aktivitesini değerlendirmek için, KAS sınıflandırma sistemi kullanıldı; KAS’u 4’ün altında olan olgularda orbitopati inaktif, KAS’u 4 ve üzerinde olan olgularda ise orbitopati aktif olarak kabul edildi. İdrar GAG tayini için olguların 24 saatlik idrarları alındı. İdrarda GAG analizi ‘dimethyl methylene blue’ yöntemine göre yapıldı. Bulgular: Tiroid orbitopatisi olan 191 olgu göz bulgularının klinik aktivitesine (43 aktif, 148 inaktif) göre gruplandırıldı. TO aktivitesi ve idrar GAG değerleri arasındaki ilişki değerlendirildiğinde; aktif orbitopatili olgularda ortalama idrar GAG değerlerinin, inaktif orbitopatili olgulardan daha yüksek olmakla birlikte, aradaki farkın anlamlı olmadığı saptandı (p=0,538, Mann-Whitney U testi). Sonuç: Tiroid orbitopati aktivitesinin belirlenmesinde kullanılabilecek yöntemlerin, TO aktivitesi ile ilişkisi halen kesinlik kazanmamıştır. Sübjektif kriterler içermesi nedeniyle, orbitopati aktivitesinin değerlendirilmesinde KAS’unun tek başına kullanılması yeterli olmamaktadır, öte yandan idrar GAG değerleri de, değerlendirmede tek başına etkili bir parametre olmaktan çok, TO aktivitesine etkili diğer belirleyicilerle birlikte değerlendirilmesi gereken yardımcı bir parametre olarak ele alınmalıdır

🔖

Cite This Article

DEMİRTAŞ, A. A., KUTLUK, S., BUYDAĞCI, G., KURAL, G. (2012). Which method should be used for evaluating the activity of thyroid orbitopathy: Clinical activity score or urinary glycosaminoglycan level?. MN Oftalmoloji, Cilt: 19 - Sayı: 4, 232–236. https://ajindex.com/articles/295762

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves' 2. Bartley GB, Fatourechi V, Kadrmas EF, et al. Long-term follow- up of Graves ophthalmopathy in an incidence cohort. Ophthalmology 1996
  2. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000
  3. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 1989
  4. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1997
  5. de Jong JGN, Wevers RA, Laarakkers C, Poorthuls BJHM. Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. Clin Chem 1989
  6. 35 1472-7. 7. Werner SC. Classification of the eye changes of Graves' disease. Am J Ophthalmol 1969
  7. Donaldson SS, Bagshaw MA, Kriss JP. Supervoltage orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 1973
  8. Spierer A, Eisenstein Z. The role of increased pressure on upgaze in the assessment of Graves ophthalmopathy. Ophthalmology 1991
  9. Konuk O, Onaran Z, Özhan Oktar S, Yücel C, Ünal M. Intraocular pressure and superior ophthalmic vein blood flow velocity in Graves' orbitopathy: relation with the clinical features. Graefes Arch Clin Exp Ophthalmol 2009
  10. Pinchera A, Wiersinga W, Glinoer D, et al. Classification of eye changes of Graves' disease. Thyroid 1992
  11. Prummel MF, Suttorp-Schulten MS, Wiersinga WM, Verbeek AM, Mourits MP, Koornneef L.A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves ophthalmopathy. Ophthal - mology 1993
  12. Kahaly G, Schuler M, Sewell AC, Bernhard G, Beyer J, Krause U. Urinary glycosaminoglycans in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1990
  13. Kahaly G, Hansen CE, Stover C, Beyer J, Otto E. Glycosaminoglycan antibodies in endocrine ophthalmopathy. Horm Metab Res 1993
  14. Kahaly G, Forster G, Hansen C. Glycosaminoglycans in thyroid eye disease. Thyroid 1998
  15. Utech CI, Khatibnia U, Winter PF, Wulle KG. MR T2 relaxation time for the as